Dr. Michael Mancano received his Bachelor of Science in Pharmacy from Temple University School of Pharmacy in 1987 and his Pharm.D. from Temple University School of Pharmacy in 1992.  He completed a postgraduate fellowship at Temple University Hospital in 1994.  Dr. Mancano has been a Clinical Professor of Pharmacy Practice at the Temple University School of Pharmacy for over twenty years and currently is the Chairman of the Pharmacy Practice Department.  Dr. Mancano maintains a clinical practice in Internal Medicine at Pennsylvania Hospital where he precepts PY4 APPE students.  In the past Dr. Mancano practiced for four years as a pharmacy manager in a community pharmacy.  He has also worked as a part-time clinical staff pharmacist for over thirteen years in community and university hospitals.  Dr. Mancano has twice been selected for the American Association of Colleges of Pharmacy Teacher of the Year Award, the Golden Apple Award at the School of Pharmacy for teaching innovation and the G. John DiGregorio, MD, PhD Award for Distinguished Teaching. 

Dr. Mancano is the co-editor of the book: Frequently Prescribed Medications: Drugs you Need to Know, which is now in revision for its third edition.  He authors a monthly column, in the journal Hospital Pharmacy, reviewing current adverse drug reactions.  His academic and scholarly interests include: educational methods/theory, active learning strategies, adverse drug reactions and their mechanisms, and clinical research methods.  Dr. Mancano currently serves as a peer reviewer for the following publications: Pediatrics, Journal of Clinical Psychopharmacology, Hospital Pharmacy, American Journal of Health-System Pharmacists, U.S. Pharmacist, Hospital Formulary and Pharmacy Times.  Dr. Mancano is currently a clinical advisor for the Institute for Safe Medication Practices (ISMP) and has held or currently holds consultantships with Aventis Pharmaceuticals, Cephalon Pharmaceuticals, Upjohn Pharmaceuticals, Pharmacia-Upjohn Pharmaceuticals, Procter & Gamble Pharmaceuticals, Rhone-Pôulenc Rorer Pharmaceuticals and Sanofi-Synthelabo Pharmaceuticals.